CLINICAL_TRIALS
research
· 2026-02-02
Clinical Trial Update: Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) [Phase 3]
Summary
A Phase 3 clinical trial evaluating emactuzumab for Tenosynovial giant cell tumor is currently active but not recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: SynOx Therapeutics Limited | Conditions: TGCT | Phase 3 | Status: ACTIVE_NOT_RECRUITING